Clinical efficacy of JAK inhibitors for rheumatoid arthritis patients with poor-prognosis factors: The ANSWER cohort study
Rheumatology 2025 Doi: 10.1093/rheumatology/keaf552 Epub ahead of print
Nozaki et al. showed that JAK inhibitor treatment provided sustained disease control (especially in high-risk RA patients) and promoted GC reduction, although TNF inhibitors remain a standard option. Nozaki et al. evaluated the clinical efficacy and continuation rates of JAK inhibitors and TNF inhibitors in RA patients with poor-prognosis factors (PPFs).
Treatment with JAK inhibitors offers higher continuation rates and better disease control than TNF inhibitors in high-risk RA patients, particularly those with anti-citrullinated protein antibodies positivity. The ability of JAK inhibitors to facilitate GC discontinuation further supports the role of JAK inhibitors treatment in achieving sustained remission. Future research should focus on the long-term safety and effectiveness of JAK inhibitors treatment, to refine RA treatment strategies.
Keywords:
